Pomegranate and Holy Basil Skin Trial Shows an Early Clinical Signal

On October 13, 2026, NutraIngredients reported on SPH-24, a proprietary blend of pomegranate peel and holy basil extracts from Samriddh Nutractive. The oral ingredient was tested against placebo in a trial focused on skin aging parameters.

The report described improvements in forehead wrinkles and several other measured skin features. It also reported no significant treatment difference in skin firmness or overall skin tone. That mixed picture makes this an early clinical signal about a specific formulation rather than a broad claim about healthier or younger-looking skin.

The Reported Benefits Were Specific to Measured Outcomes

According to NutraIngredients, the trial reported statistically significant reductions in forehead wrinkle number and wrinkle area compared with placebo. Wrinkle-area percentage also improved. These are separate measurements of the forehead findings, not evidence of a change in every facial feature.

The report also described significant improvements in hydration and elasticity. It included improvements in transepidermal water loss, abbreviated as TEWL, alongside melanin index and pigmentation measures. Erythema was another reported outcome with a significant improvement.

Firmness and overall skin tone stood apart from those positive results. NutraIngredients reported no significant treatment difference for either outcome. A clear account of the study should give these findings the same visibility as the wrinkle and hydration results.

That distinction matters when reading a headline about skin aging. The most faithful summary is a set of reported changes in particular measurements. It is not a statement that the blend improved all aspects of skin appearance or structure.

Safety findings were favorable during the reported trial. NutraIngredients said there were no treatment-related or serious adverse events. The report also described no clinically significant laboratory or vital-sign abnormalities.

The Trial Tested a Defined Population Over 12 Weeks

NutraIngredients described the study as randomized, double-blind and placebo-controlled. The reported trial had a defined population and comparison:

• Participants: 80 women aged 30 to 55.
• Duration: 12 weeks.
• Comparison: Daily SPH-24 versus daily placebo.

The wrinkle timeline deserves careful reading. A reduction in wrinkle number was reported from week 4. Significant reductions in the reported forehead-wrinkle measures were described at week 12.

Those statements do not mean that all reported outcomes changed at week 4. The earlier finding was specifically about wrinkle number. Keeping each result attached to its own timing avoids turning a narrow observation into a claim about the entire formulation.

The placebo comparison is central to the reported findings. The claim in the coverage is a difference between treatment groups, not merely that participants' skin changed over time. That is why “compared with placebo” belongs in the interpretation rather than being left out of a product summary.

For readers, statistical significance is only part of the question. The other part is whether a change is noticeable or meaningful in daily life. A controlled trial result should not be treated as a forecast of an individual person's experience.

Missing Details Limit the Clinical Interpretation

The main limitation is the gap between reported significance and the information needed to judge the size of the benefit. NutraIngredients identifies the publication as Clinical and Experimental Dermatology and Therapies. Its coverage does not supply several details that matter when assessing a clinical claim:

• Effect sizes and confidence intervals, which are needed to assess the magnitude and precision of the reported changes.
• Detailed participant flow, which would help clarify how the enrolled participants were represented in the results.
• The daily dose, so the study's regimen cannot be reconstructed from the summary.
• Funding and relevant commercial-conflict information, so the study's independence is not established by this coverage.

These are gaps in the available account, not proof that the trial itself lacked those details. They belong in an assessment of the full paper before strong claims are made about clinical importance or independence.

The report quotes the researchers as supporting the blend's potential as a botanical nutricosmetic for healthy skin aging. That is the study authors' interpretation. It is best read alongside the measured outcomes rather than as a separate finding that aging was prevented or reversed.

The coverage also does not provide independent replication. The evidence discussed here concerns one proprietary blend in women within the reported age range. It does not establish equivalent results for other pomegranate or holy basil formulations.

The article does not report that collagen was measured. An elasticity result should therefore not be relabeled as evidence that SPH-24 increases collagen. Readers focused on that question can consult Younell's discussion of collagen-trial quality as a separate line of evidence.

The safety findings also have a defined boundary: they describe the reported trial period. They do not establish suitability for every person or provide individualized guidance about health conditions and medications.

The Report Is Most Useful for Evaluating Claims

The practical value of this report is a more precise way to evaluate a supplement claim. Match the claim to the outcome actually reported rather than to the broad phrase “skin aging.” For example, a firmness claim would not reflect this trial's findings.

Formulation identity is another useful checkpoint. A reader considering a product can ask whether it contains the specific blend that was studied. Ingredient names alone do not answer that question.

It is also reasonable to be interested in the result without turning it into a purchasing decision. The useful question is whether the reported endpoint matches the benefit being sought. That keeps the discussion centered on evidence rather than on the appeal of a botanical ingredient.

Personal decisions belong in a discussion with a qualified healthcare professional, particularly when existing health conditions or medications are relevant. This report is research context for that conversation rather than a dosing guide.

Younell's broader review of oral skin-supplement evidence offers related reading. For a different research format, our assessment of topical-peptide studies provides another example of separating measured outcomes from wider product claims.

Further Testing Is the Next Step

Samriddh founder and CEO Aditya Jain described the study as an “important first step,” according to NutraIngredients. He said further trials were planned through 2027. That is a company's research plan, not a finding about what future trials will show.

The most useful next question is whether further testing reproduces the reported pattern of improvements and clarifies their practical value. A meaningful follow-up would also keep the unchanged outcomes visible rather than focusing only on favorable measurements.

For now, SPH-24 has a reported clinical signal in several skin parameters. Firmness and overall skin tone did not show significant treatment differences. The balanced takeaway is interest in a specific trial result, not an assumption that botanical supplements broadly change the course of skin aging.

Sources

1. Newly launched extract shows positive results on skin in four weeks